New agents for the treatment of hepatitis C virus – focus on telaprevir

References

• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1: 74–81.
   Google Scholar
• Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5–19.
   PubMed Web of Science ®Google Scholar
• Sumpter R Jr, Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol. 2005;79(5):2689–2699.
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF Proc Natl Acad Sci U S A. 2005;102(8):2992–2997.
   PubMed Web of Science ®Google Scholar
• Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN- beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA. 2006;103(15):6001–6006.
   Web of Science ®Google Scholar
• Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3–4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother. 2006;50(5):1813–1822.
   PubMed Web of Science ®Google Scholar
• Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3–4A serine protease. Antimicrob Agents Chemother. 2006;50(3):899–909.
   PubMed Web of Science ®Google Scholar
• Kwong AD, Kauffmann RS, Hurter P, Mueller P. Discovery and devleopment of telaprevir: an NS3–4A protease inhibitoir for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 2011 ;29(11): 993–1003.
   Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131(4):997–1002.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132(5):1767–1777.
   PubMed Web of Science ®Google Scholar
• Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of tel- aprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46(3):640–648.
   Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46(3):631–639.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008;49(2):163–169.
   PubMed Web of Science ®Google Scholar
• Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors tel- aprevir (VX-950) and danoprevir (ITMN-191). Hepatology. 2011;53(4):1090–1099.
   Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):254–264.
   Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416.
   PubMed Web of Science ®Google Scholar
• Incivek® (prescribing information). Available from: http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf. Accessed July 8, 2012.
   Google Scholar
• Jacobson IM, Dusheiko GM, McHutchison JG, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of the Phase 3 ADVANCE study. Hepatology. 2010;52 Suppl 1:Abstr 211.
   Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–1024.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
   PubMed Web of Science ®Google Scholar
• Foster GR, Zeuzem S, Andreone P, et al Subanalyses of the telaprevir lead-in arm in the REALIZE study: Response at week 4 is not a substitute for prior null response categorization. J Hepatol. 2011;54 Suppl 1: S3(A6).
   Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–129.
   PubMed Web of Science ®Google Scholar
• Suppiah V Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–1104.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–1109.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. JHepatol. 2011;54:Abstr 1369.
   Google Scholar
• Gellad ZF, Naggie S, Reed SD, et al. The cost-effectiveness of a telaprevir-inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the C/C IL28B polymorphism. Hepatology. 2011;54 Suppl 4:417A(118).
   Google Scholar
• Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. March 27, 2012. [Epub ahead of print.]
   Google Scholar
• Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost- effectiveness analysis. Ann Intern Med. 2012;156(4):279–290.
   PubMed Web of Science ®Google Scholar
• Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with tel- aprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J Hepatol. 2011;54:S6(A13).
   Google Scholar
• Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology. 2011;53(6):1801–1808.
   Web of Science ®Google Scholar
• Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010;2(30):30ra32.
   PubMed Web of Science ®Google Scholar
• Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–1850.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment-naive, genotype 1 HCV subjects. Hepatology. 2010;52 Suppl 1:Abstr LB1.
   Google Scholar
• Zeuzem S, Soriano V Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, ± ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2. J Hepatol. 2012;56 Suppl:Abstr 101.
   Google Scholar
• Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct- acting antivirals. J Hepatol. 2012;56(2):455–463.
   PubMed Web of Science ®Google Scholar
• Sulkoski MS, Roberts S, Afdhal N, Andreone P, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virological response in phase 3 studies. J Hepatol. 2012;56 Suppl 2: S459(A1162).
   Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–2428.
   PubMed Web of Science ®Google Scholar
• Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic nonresponders. First results of the French Early Access program (ANRS CO20-CUPIC). J Hepatol. 2012;56 Suppl 2:S4(A8).
   Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie A, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396.
   PubMed Web of Science ®Google Scholar
• Coilly A, Roche B, D. Botta-Fridlund D, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol. 2012; 56(A47).
   Google Scholar
• Drug interaction charts. Available from: http://www.hep-druginteractions.org. Accessed July 8, 2012.
   Google Scholar
• Dieterich DT, Soriano V Sherman K. Telaprevir in combination with pegylated interferon-alfa-2a + ribavirin in HCV/HIV co-infected patients: a 24-week treatment interim analysis. Paper presented at the 19th Conference on Retroviruses and Opportunistic Infections, March 5–8, 2012, Seattle, WA.
   Google Scholar
• Fried M, Buti M, Dore GJ, Flisiak R, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR Phase IIB study. Hepatology. 2011;54 Suppl 4:1429A(LB-1425).
   Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir- based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ ribavirin. J Hepatol. 2011;54:A5.
   Google Scholar